Ibrutinib

• A Randomized, Open-label, Phase 3 study of the Combination of Ibrutinib plus Venetoclax versus Chlorambucil plus Obinutuzumab for the First-… Ended
  2023-503469-49-00 Phase III 8 countries Janssen - Cilag International
• ENRICH - Randomised, open label study of Rituximab/Ibrutinib vs Rituximab/Chemotherapy in older patients with untreated mantle cell lymphoma Ended
  2024-514275-18-00 Phase II/III 4 countries Region Skane; University Hospitals Plymouth NHS Trust
• Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib Ended
  2023-507329-40-00 Phase IV 7 countries AbbVie Deutschland GmbH & Co. KG
• A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High R… Ended
  2023-509347-27-00 Phase III 2 countries Acerta Pharma B.V.
• A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study Ended
  2023-503803-27-00 Phase III 8 countries Janssen - Cilag International
• A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell … Ended
  2022-501259-10-00 Phase II 7 countries Kite Pharma Inc.
• A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell … Ended
  2022-501260-18-00 Phase II 7 countries Kite Pharma Inc.
• Seamless Phase 2/3 Study of Ibrutinib With Rituximab in Relapsed/Refractory Mantle Cell Lymphoma Ended
  2023-503618-64-00 Phase II 3 countries Janssen - Cilag International
• Phase 1/2 Dose Finding, Safety and Efficacy Study of Ibrutinib in Pediatric Subjects with Chronic Graft Versus Host Disease (cGVHD) Ended
  2023-507330-24-00 Phase I/II 5 countries AbbVie Deutschland GmbH & Co. KG
• Tisagenlecleucel in adult patients with aggressive B-cell non-Hodgkin lymphoma Ended
  2023-508343-48-00 Phase III 7 countries Novartis Pharma AG
• Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3) (ZUMA-2) Ended
  2023-506641-35-00 Phase II 4 countries Kite Pharma Inc.
• A prospective, multicenter, phase-II trial of ibrutinib plus venetoclax in physically fit patients with creatinine clearance ≥ 30 ml/min who… Ended
  2023-510557-42-00 Phase II 6 countries Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
• A study of Ibrutinib in combination with Rituximab versus Placebo in combination with Rituximab in treatment of patients with Follicular Lym… Ended
  2023-507271-21-00 Phase III 11 countries AbbVie Deutschland GmbH & Co. KG
• autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized Europea… Ended
  2024-511235-10-00 Phase III 12 countries Klinikum der Universitaet Muenchen AöR
• A phase I/II trial of Obinutuzumab, ABT-199 (GDC-0199) plus Ibrutinib in Relapsed / Refractory Mantle Cell Lymphoma patients (OAsIs) Ended
  2024-516750-21-00 Phase I/II 1 country Centre Hospitalier Universitaire De Nantes
• A Phase II study evaluating efficacy of KTE-X19 CAR-T cell therapy in Relapsed or Refractory Mantle-Cell Lymphoma achieving a partial respon… Expired
  2022-502907-31-00 Phase II 1 country Fondazione IRCCS Istituto Nazionale Dei Tumori

Showing 25–40 of 40 trials